Lilly's Alzheimer's drug Kisunla receives EU approval for use in specific patient populations.

According to the Zhtng Finance APP, Eli Lilly and Company's (LLY.US) Alzheimer's drug Kisunla has received support from the European regulatory agency and has been approved for use in specific patient groups. This development may pave the way for it to become the second drug in the European region to delay the most common cause of dementia in the elderly.